Literature DB >> 22172570

Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders.

Murat Gök1, Daniëlle A M Heideman, Folkert J van Kemenade, Anton L M de Vries, Johannes Berkhof, Lawrence Rozendaal, Jeroen A M Beliën, Lucy Overbeek, Milena Babović, Peter J F Snijders, Chris J L M Meijer.   

Abstract

BACKGROUND: Self-sampling for high-risk human papillomavirus (hrHPV) testing is accepted by up to 30% of non-attendees to the regular cervical screening programme. Here, the yield of cervical intraepithelial neoplasia (CIN)2 or worse (≥ CIN2) and CIN3 or worse (≥ CIN3) of 15, 274 HPV self-sampling responders amongst non-attendees were compared to that of 176, 027 women participating in regular screening in the same period and in the same region. We also analysed which subpopulations amongst non-attendees are targeted by HPV self-sampling, and which characteristics relate to hrHPV prevalence and yield of ≥ CIN2/≥ CIN3.
METHOD: Data from two consecutive self-sampling studies were pooled. ≥ CIN2/≥ CIN3 yields, screening history, age and ethnic status were retrieved from centralised pathology and screening databases, respectively. A logistic regression model was fitted to analyse method of invitation, ethnicity, age group, and screening history as predictors for response rate, hrHPV presence and ≥ CIN2/≥ CIN3 in non-attendees. For screening history analyses, women < 34 years were excluded since it was the first screening round in their life.
FINDINGS: ≥ CIN2/≥ CIN3 yields of HPV self-sampling responders were higher than those of screening participants (≥ CIN2: relative risk (RR) = 1.6, 95% confidence interval = 1.4-1.9; ≥ CIN3: RR = 1.8, 95%CI = 1.5-2.1 with relative risk values increasing with age (test of homogeneity:≥ CIN2: p = 0.04; ≥ CIN3: p=0.03). Native Dutch non-attendees responded better than immigrants (32% versus 22%, p<0.001) and those screened in the previous round revealed a higher response than underscreened (i.e. previous smear taken >7 years ago) or never screened (34% versus 25%, p<0.001) women. Strikingly, amongst under- and never screened women aged ≥ 39 years, never screened women responded better (25% versus 23%, p<0.001). ≥ CIN2 rates were higher amongst responding native Dutch women than immigrants (p<0.01), and higher in under-/never screened women than in women screened in the previous round (p<0.01).
INTERPRETATION: Offering hrHPV self-sampling increases the efficacy of the screening programme by targeting a substantial portion of non-attendees of all ethnic groups who have not regularly been screened and are at highest risk of ≥ CIN2.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22172570     DOI: 10.1016/j.ejca.2011.11.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

Review 1.  Acceptability, Feasibility and Uptake of HPV Self-Sampling Among Immigrant Minority Women: a Focused Literature Review.

Authors:  Sarah Marshall; Mandana Vahabi; Aisha Lofters
Journal:  J Immigr Minor Health       Date:  2019-12

2.  Assessing the impact of mailing self-sampling kits for human papillomavirus testing to unscreened non-responder women in Manitoba.

Authors:  F Jalili; C O'Conaill; K Templeton; R Lotocki; G Fischer; L Manning; K Cormier; K Decker
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

3.  Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States.

Authors:  Jennifer S Smith; Andrea C Des Marais; Allison M Deal; Alice R Richman; Carolina Perez-Heydrich; Belinda Yen-Lieberman; Lynn Barclay; Jerome Belinson; Allen Rinas; Noel T Brewer
Journal:  Sex Transm Dis       Date:  2018-01       Impact factor: 2.830

Review 4.  New strategies for human papillomavirus-based cervical screening.

Authors:  Attila Lorincz; Alejandra Castanon; Anita Wey Wey Lim; Peter Sasieni
Journal:  Womens Health (Lond)       Date:  2013-09

5.  Consultation rates in cervical screening non-attenders: opportunities to increase screening uptake in GP primary care.

Authors:  Anita Wey Wey Lim; Peter Sasieni
Journal:  J Med Screen       Date:  2015-03-05       Impact factor: 2.136

6.  Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter.

Authors:  P Giorgi Rossi; C Fortunato; P Barbarino; S Boveri; S Caroli; A Del Mistro; A Ferro; C Giammaria; M Manfredi; T Moretto; A Pasquini; M Sideri; M C Tufi; C Cogo; E Altobelli
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

7.  Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.

Authors:  Lise M A De Strooper; Viola M J Verhoef; Johannes Berkhof; Albertus T Hesselink; Helena M E de Bruin; Folkert J van Kemenade; Remko P Bosgraaf; Ruud L M Bekkers; Leon F A G Massuger; Willem J G Melchers; Renske D M Steenbergen; Peter J F Snijders; Chris J L M Meijer; Daniëlle A M Heideman
Journal:  Gynecol Oncol       Date:  2016-03-03       Impact factor: 5.482

8.  Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta.

Authors:  Philip E Castle; Julia C Gage; Edward E Partridge; Alfio Rausa; Patti E Gravitt; Isabel C Scarinci
Journal:  BMC Infect Dis       Date:  2013-01-07       Impact factor: 3.090

9.  Attitudes towards cytology and human papillomavirus self-sample collection for cervical screening among Hindu women in London, UK: a mixed methods study.

Authors:  Louise Cadman; Lesley Ashdown-Barr; Jo Waller; Anne Szarewski
Journal:  J Fam Plann Reprod Health Care       Date:  2014-02-12

Review 10.  The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs.

Authors:  Paolo Giorgi Rossi; Flavia Baldacchini; Guglielmo Ronco
Journal:  Front Oncol       Date:  2014-02-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.